Try our mobile app
Screener
Company
Price and
change
Revenue Growth
last / hist
EV /
LTM
EBITDA
(p75)
EV/
Sales
EBITDA LTM
/ Revenue
FCF LTM
/ Revenue
Next GAAP report
Year div-d yield
FCF Yield LTM
128.0%  /
87.4%
26.5x
16.6x
2.1x
7.8%
5.3%
..
0.5%
3.1% 
16.4%  /
73.7%
12.2x
12.2x
2.3x
19.2%
19.6%
..
0.0%
15.4% 
8.7%  /
73.7%
2.2x
2.2x
0.8x
35.8%
-2.3%
..
0.0%
-3.9% 
139.7%  /
67.2%
11.2x
16.4x
1.9x
34.7%
-38.8%
..
0.9%
-20.1% 
-76.8%  /
58.5%
5.6x
5.6x
2.4x
41.8%
-33.8%
..
0.0%
-38.9% 
>200%  /
49.7%
15.8x
22x
8.3x
52.5%
-37.0%
2026-03-10
2.9%
-4.8% 
8.8%  /
48.8%
10.4x
9x
3.2x
30.5%
-35.4%
2026-03-02
0.0%
-13.7% 
6.2%  /
45.4%
4.2x
4.2x
1.8x
43.6%
-110.0%
2026-03-04
4.4%
-183.6% 
26.6%  /
44.0%
45.6x
43.6x
6.3x
13.8%
-6.1%
2026-02-24
0.0%
-1.0% 
>200%  /
41.1%
4.1x
4.7x
1x
24.8%
-29.8%
2026-02-27
0.0%
-46.2% 
142.3%  /
38.2%
6.1x
6x
2.6x
43.6%
-3.8%
2026-03-11
0.0%
-1.6% 
11.2%  /
38.0%
13.7x
11.2x
7.3x
52.8%
149.6%
2026-02-24
4.3%
19.4% 
11.5%  /
31.8%
3.7x
10.6x
1.5x
41.4%
6.7%
..
1.6%
5.5% 
-19.8%  /
30.9%
8.8x
20.7x
0.7x
7.9%
-5.2%
2026-02-27
0.0%
-31.7% 
4.6%  /
30.3%
29.3x
31.6x
3.2x
11.1%
-0.2%
2026-02-25
6.9%
-0.1% 
18.2%  /
29.1%
9.4x
8.9x
6.1x
64.7%
36.3%
2026-02-24
11.5%
5.8% 
7.9%  /
28.9%
30.5x
15.8x
2x
4.5%
4.1%
..
0.4%
2.0% 
33.9%  /
25.4%
21.1x
18.2x
11.9x
56.4%
17.9%
2026-02-24
3.9%
1.6% 
132.4%  /
22.6%
6.3x
8.8x
3.4x
53.1%
-11.4%
..
4.2%
-4.2% 
4.0%  /
22.3%
1.7x
8.6x
0.3x
16.8%
5.7%
..
11.8%
31.0% 
3.3%  /
20.1%
11.6x
7.7x
2.5x
21.7%
5.0%
..
5.1%
2.6% 
15.2%  /
18.7%
4.3x
6.7x
1.8x
41.1%
-52.5%
..
0.0%
-3 371.2% 
6.2%  /
18.5%
3.8x
6.1x
0.2x
4.7%
-1.5%
2026-03-04
6.5%
-13.6% 
-4.3%  /
17.6%
4.4x
8.4x
1.4x
32.3%
8.1%
..
6.9%
5.3% 
10.7%  /
17.0%
10.4x
10.5x
1.8x
17.5%
1.9%
2026-02-24
3.5%
1.2% 
2.3%  /
12.8%
9.3x
5.8x
1.3x
13.6%
65.2%
..
0.7%
49.5% 
-17.3%  /
12.6%
3.3x
2.6x
6.2x
207.2%
140.3%
..
4.7%
22.7% 
6.1%  /
11.7%
5.8x
5.2x
3x
51.6%
26.1%
..
9.2%
10.7% 
-65.8%  /
11.3%
9.2x
10.5x
2x
19.3%
-63.0%
2026-03-10
2.3%
-31.0% 
160.8%  /
11.3%
6.9x
6.9x
0.6x
8.2%
18.3%
..
0.0%
37.3% 
1.8%  /
11.2%
5.9x
5.9x
0.8x
14.3%
9.3%
2026-02-23
2.5%
12.3% 
-64.9%  /
7.9%
10.9x
7.6x
3.2x
31.0%
-52.6%
..
2.1%
-16.7% 
>200x
>200x
256.6x
0.0%
0.0%
..
0.0%
--- 
3.5%  /
-0.6%
29.3x
42.9x
7.1x
24.3%
8.4%
..
8.1%
1.2% 
9.6%  /
-2.5%
6x
6.1x
2.3x
38.5%
-74.4%
..
2.7%
-52.7% 
27.5%  /
-4.3%
>200x
>200x
0.8x
0.1%
-8.5%
2026-03-11
0.0%
-82.1% 
-9.7%  /
-8.6%
6.5x
6.9x
1.8x
27.4%
14.2%
2026-02-23
0.0%
5.4% 
0.5%  /
-8.6%
4.1x
3.6x
1.8x
43.4%
-16.6%
2026-03-05
7.6%
-15.3% 
-0.5%  /
-16.5%
5.4x
5.7x
1.1x
20.4%
-5.1%
2026-03-11
4.8%
-16.2% 
>200%  /
-19.9%
10.8x
11.7x
3.3x
24.4%
45.2%
2026-03-04
0.9%
13.8% 
Trending screeners:
@electric-vehicles
@saas
@cannabis-players
@china
Latin America
India
Dividends
@REITs
@adtech
@airlines
@artificial-intelligence
@auto-parts
@cloud-computing
@crypto
@cybersecurity
@e-commerce
@edtech
@finance-and-technology
@gaming
@internet-of-things
@oil-refining
@real-estate-tech
@renewable-energy
@vaccine-makers

Reviews

2026-02-28
#reports #ACT

[Enact Holdings, Inc.](https://eninvs.com/all.php?name=ACT) (Insurance — Specialty) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195820)
(2026-02-03, After Market Close):

- Revenue +7.2% YoY (vs +2.0% in previous quarter and historical rate +4.2%)
- Net Income +9.9% YoY (vs +3.8% in previous quarter and historical rate +1.6%)
- Net Income margin 56.5% increased compared to 55.1% same period last year
- P/E multiple is 8.7x compared to historical level (75th percentile) of 8.3x
- P/S multiple is 5x
- Price to book: 1.1x

The company showed EPS +$4.54 per share. At the opening of the session the share price went up +6.9%
2026-02-28
#reports #AYTU

[Aytu Biopharma](https://eninvs.com/all.php?name=AYTU) (Drug Manufacturers — Specialty and Generic) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195692)
(2025-09-23, After Market Close):

- Revenue -6.3% YoY (vs -17.6% in previous quarter and historical rate -15.0%)
- EBITDA margin -13.3% decreased compared to -12.5% same period last year
- Net Debt increased by $49 mln over the past reporting period (179.5% of market cap)
- FCF (LTM) +$0 bln (positive), 120.9% of market cap
- EV/EBITDA multiple is 45.3x compared to historical level (75th percentile) of 18x
- EV/Sales multiple is 0.7x

At the opening of the session the share price went down -12.4%
2026-02-28
#reports #ASB

[Associated Banc-Corp](https://eninvs.com/all.php?name=ASB) (Banks — Regional) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195686)
(2026-01-22, After Market Close):

- Revenue +154.1% YoY (vs +28.7% in previous quarter and historical rate +44.2%)
- Net Income margin 44.2% increased compared to -91.8% same period last year
- P/E multiple is 12.2x compared to historical level (75th percentile) of 34.2x
- P/S multiple is 2.4x
- Price to book: 0.8x

The company showed EPS +$2.81 per share. At the opening of the session the share price went up +2.0%
2026-02-28
#reports #AMWL

[American Well Corporation](https://eninvs.com/all.php?name=AMWL) (Health Information Services) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195677)
(2026-02-12, After Market Close):

- Revenue -22.5% YoY (vs -1.6% in previous quarter and historical rate -1.3%)
- EBITDA margin -34.5% increased compared to -67.6% same period last year
- Net Debt increased by $70 mln over the past reporting period (99.8% of market cap)
- FCF (LTM) -$0.1 bln (negative), 176.8% of market cap
- EV/EBITDA multiple is 0.6x compared to historical level (75th percentile) of 1.5x
- EV/Sales multiple is -0.4x

2026-02-28
#reports #AIHS

[Senmiao Technology Limited](https://eninvs.com/all.php?name=AIHS) (Credit Services) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195668)
(2026-02-13, Before Market Open):

- Net Income margin -100.0% decreased compared to -50.0% same period last year
- P/S multiple is 4.3x
- Price to book: -97.2x
2026-02-28
#reports #ACRS

[Aclaris Therapeutics](https://eninvs.com/all.php?name=ACRS) (Biotechnology) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195664)
(2026-02-26, Before Market Open):

- Revenue -94.4% YoY (vs -55.6% in previous quarter and historical rate +40.8%)
- EBITDA margin -2300.0% decreased compared to -238.9% same period last year
- Net Debt decreased by $43 mln over the past reporting period (9.2% of market cap)
- FCF (LTM) +$0 bln (positive), 1.9% of market cap
- EV/Sales multiple is 37.7x

2026-02-28
#reports #BANR

[Banner](https://eninvs.com/all.php?name=BANR) (Banking service provider) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195459)
(2026-01-21, After Market Close):

- Revenue +217.4% YoY (vs +7.7% in previous quarter and historical rate +17.8%)
- Net Income margin 32.4% increased compared to -3.6% same period last year
- P/E multiple is 8.5x compared to historical level (75th percentile) of 37.9x
- P/S multiple is 2.3x
- Price to book: 1.1x

The company showed EPS +$5.67 per share. At the opening of the session the share price went down -0.7%
2026-02-28
#reports #BANF

[BancFirst](https://eninvs.com/all.php?name=BANF) (Banking service provider) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195458)
(2026-01-19, Before Market Open):

- Revenue +20.8% YoY (vs +10.5% in previous quarter and historical rate -0.7%)
- Net Income +18% YoY (vs +14.3% in previous quarter and historical rate +17.0%)
- Net Income margin 46.1% decreased compared to 47.2% same period last year
- P/E multiple is 16x compared to historical level (75th percentile) of 18.8x
- P/S multiple is 7.7x
- Price to book: 2x

The company showed EPS +$7.22 per share
2026-02-28
#reports #AIZ

[Assurant](https://eninvs.com/all.php?name=AIZ) (Insurance services provider) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195448)
(2026-02-10, After Market Close):

- Revenue +12.3% YoY (vs +7.0% in previous quarter and historical rate +6.0%)
- Net Income -20.2% YoY (vs +2.2% in previous quarter and historical rate +37.4%)
- Net Income margin 6.7% decreased compared to 9.5% same period last year
- P/E multiple is 11.1x compared to historical level (75th percentile) of 11.6x
- P/S multiple is 1x
- Price to book: 2.2x
2026-02-28
#reports #AFL

[Aflac](https://eninvs.com/all.php?name=AFL) (Insurance services provider) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195446)
(2026-02-04, After Market Close):

- Revenue -10.5% YoY (vs +43.0% in previous quarter and historical rate -3.9%)
- Net Income -26.6% YoY (vs +609.7% in previous quarter and historical rate +17.2%)
- Net Income margin 28.3% decreased compared to 34.6% same period last year
- P/E multiple is 11.7x compared to historical level (75th percentile) of 11.3x
- P/S multiple is 3.2x
- Price to book: 2.1x

The company showed EPS +$6.86 per share. At the opening of the session the share price went up +3.2%
2026-02-28
#reports #ADUS

[Addus HomeCare](https://eninvs.com/all.php?name=ADUS) (Social and medical services at home provider of ) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195445)
(2026-02-23, After Market Close):

- Revenue +35.1% YoY (vs +7.0% in previous quarter and historical rate +12.4%)
- EBITDA +73.5% YoY (vs +19.2% in previous quarter and historical rate +18.6%)
- EBITDA margin 15.8% increased compared to 12.3% same period last year
- Net Debt increased by $263 mln over the past reporting period (13.2% of market cap)
- FCF (LTM) +$0.3 bln (positive), 14.2% of market cap
- EV/EBITDA multiple is 14.1x compared to historical level (75th percentile) of 17.3x
- EV/Sales multiple is 1.7x

2026-02-28
#reports #BRID

[Bridgford Foods Corporation](https://eninvs.com/all.php?name=BRID) (Packaged Foods) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195243)
(2026-01-19, After Market Close):

- Revenue +38.2% YoY (vs +180.0% in previous quarter and historical rate +18.9%)
- EBITDA -400% YoY (vs -60.0% in previous quarter)
- EBITDA margin -11.8% decreased compared to 5.5% same period last year
- Net Debt increased by $7 mln over the past reporting period (10.0% of market cap)
- FCF (LTM) -$0 bln (negative), 2.9% of market cap
- EV/Sales multiple is 0.2x

The company showed EPS -$1.47 per share
2026-02-28
#reports #BDSX

[Biodesix](https://eninvs.com/all.php?name=BDSX) (Diagnostics and Research) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195237)
(2025-11-03, Before Market Open):

- Revenue +45% YoY (vs +22.2% in previous quarter and historical rate +32.7%)
- EBITDA margin -6.9% increased compared to -35.0% same period last year
- Net Debt decreased by $2 mln over the past reporting period (2.7% of market cap)
- FCF (LTM) -$0 bln (negative), 27.0% of market cap
- EV/Sales multiple is 1.4x

At the opening of the session the share price went down -1.0%
2026-02-27
#reports #XRAY

[DENTSPLY SIRONA](https://eninvs.com/all.php?name=XRAY) (Dental materials and equipment manufacturer) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195211)
(2026-02-26, After Market Close):

- Revenue +49.4% YoY (vs -4.9% in previous quarter and historical rate +9.5%)
- EBITDA margin -3.5% increased compared to -23.4% same period last year
- Net Debt decreased by $55 mln over the past reporting period (2.0% of market cap)
- FCF (LTM) -$0.1 bln (negative), 2.3% of market cap
- EV/Sales multiple is 0.8x

2026-02-27
#reports #XPOF

[Xponential Fitness, Inc.](https://eninvs.com/all.php?name=XPOF) (Leisure) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue 0% YoY (vs -1.2% in previous quarter and historical rate +10.1%)
- EBITDA margin -7.2% increased compared to -56.6% same period last year
- Net Debt increased by $125 mln over the past reporting period (45.8% of market cap)
- FCF (LTM) +$1.6 bln (positive), 582.7% of market cap
- EV/EBITDA multiple is 34.1x compared to historical level (75th percentile) of 67.1x
- EV/Sales multiple is 3.5x

2026-02-27
#reports #WWW

[Wolverine World Wide](https://eninvs.com/all.php?name=WWW) (Clothing/shoes/accessories manufacturer) reported for 2025 q4
(2026-02-26, Before Market Open):

- Revenue +4.6% YoY (vs +6.8% in previous quarter and historical rate -10.1%)
- EBITDA +19.6% YoY (vs +9.1% in previous quarter and historical rate +25.8%)
- EBITDA margin 10.6% increased compared to 9.3% same period last year
- Net Debt decreased by $132 mln over the past reporting period (9.2% of market cap)
- FCF (LTM) -$0 bln (negative), 2.3% of market cap
- EV/EBITDA multiple is 10.2x compared to historical level (75th percentile) of 15.3x
- EV/Sales multiple is 1.1x

2026-02-27
#reports #WRBY

[Warby Parker Inc.](https://eninvs.com/all.php?name=WRBY) (Medical Instruments and Supplies) reported for 2025 q4
(2026-02-26, Before Market Open):

- Revenue +11% YoY (vs +15.6% in previous quarter and historical rate +13.4%)
- EBITDA +71.4% YoY (vs +333.3% in previous quarter and historical rate +89.3%)
- EBITDA margin 5.7% increased compared to 3.7% same period last year
- Net Debt decreased by $5 mln over the past reporting period (0.1% of market cap)
- FCF (LTM) +$0 bln (positive), 0.6% of market cap
- EV/EBITDA multiple is 94.9x compared to historical level (75th percentile) of 202.8x
- EV/Sales multiple is 3.8x

2026-02-27
#reports #VTRS

[Viatris](https://eninvs.com/all.php?name=VTRS) (Medicines manufacturer) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195208)
(2026-02-26, Before Market Open):

- Revenue +5% YoY (vs +0.2% in previous quarter and historical rate -4.1%)
- EBITDA -1% YoY (vs -20.9% in previous quarter and historical rate -20.6%)
- EBITDA margin 35.7% decreased compared to 37.9% same period last year
- Net Debt decreased by $372 mln over the past reporting period (2.3% of market cap)
- FCF (LTM) -$0 bln (negative), 0.2% of market cap
- EV/EBITDA multiple is 177.2x compared to historical level (75th percentile) of 15.1x
- EV/Sales multiple is 2x

2026-02-27
#reports #VTEX

[VTEX](https://eninvs.com/all.php?name=VTEX) (Software — Application) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=6&id=230226)
(2026-02-26, After Market Close):

- Revenue +11.5% YoY (vs +9.8% in previous quarter and historical rate +22.0%)
- EBITDA margin 20.6% increased compared to -24.6% same period last year
- Net Debt decreased by $169 mln over the past reporting period (26.3% of market cap)
- FCF (LTM) -$0 bln (negative), 0.6% of market cap
- EV/EBITDA multiple is 23.9x compared to historical level (75th percentile) of 186.4x
- EV/Sales multiple is 1.9x

2026-02-27
#reports #VCEL

[Vericel](https://eninvs.com/all.php?name=VCEL) (Medical services provider) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195207)
(2026-02-26, Before Market Open):

- Revenue +24% YoY (vs +17.2% in previous quarter and historical rate +18.7%)
- EBITDA +30% YoY (vs +500.0% in previous quarter)
- EBITDA margin 28.0% increased compared to 26.7% same period last year
- Net Debt decreased by $4 mln over the past reporting period (0.2% of market cap)
- FCF (LTM) +$0 bln (positive), 1.1% of market cap
- EV/EBITDA multiple is 92.8x compared to historical level (75th percentile) of 724.3x
- EV/Sales multiple is 6.7x

2026-02-27
#reports #TTEC

[TTEC](https://eninvs.com/all.php?name=TTEC) (IT services provider) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195206)
(2026-02-26, After Market Close):

- Revenue +0.5% YoY (vs -1.9% in previous quarter and historical rate -4.2%)
- EBITDA -475% YoY (vs -7.9% in previous quarter and historical rate -26.3%)
- EBITDA margin -26.3% decreased compared to 7.1% same period last year
- Net Debt increased by $8 mln over the past reporting period (4.6% of market cap)
- FCF (LTM) +$0.1 bln (positive), 49.1% of market cap
- EV/Sales multiple is 0.5x